Masahiro Sugita
Director/Board Member bei HORIBA, LTD.
Profil
Masahiro Sugita is an Independent Outside Director at The 77 Bank, Ltd.
since 2013 and at Horiba Ltd.
since 2006.
He previously worked as General Director-International Department at Bank of Japan, Director-Overseas Investment Research Institute at Export-Import Bank of Japan, and Auditor at MSD (Japan) Co., Ltd.
Aktive Positionen von Masahiro Sugita
| Unternehmen | Position | Beginn |
|---|---|---|
| HORIBA, LTD. | Director/Board Member | 18.01.2010 |
| THE 77 BANK, LTD. | Director/Board Member | 01.06.2013 |
Ehemalige bekannte Positionen von Masahiro Sugita
| Unternehmen | Position | Ende |
|---|---|---|
| BANK OF JAPAN | Corporate Officer/Principal | - |
| Export-Import Bank of Japan | Corporate Officer/Principal | - |
MSD (Japan) Co., Ltd.
 MSD (Japan) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD (Japan) Co., Ltd. is a company that focuses on Japanese domestic development pipeline. The private company is based in Tokyo, Japan. The company's description states that it is a page of the clinical trial guide, which suggests that it is involved in the development and testing of new pharmaceutical products. | Comptroller/Controller/Auditor | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| THE 77 BANK, LTD. | Finance |
| HORIBA, LTD. | Producer Manufacturing |
| BANK OF JAPAN | Government |
| Private Unternehmen | 2 |
|---|---|
MSD (Japan) Co., Ltd.
MSD (Japan) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD (Japan) Co., Ltd. is a company that focuses on Japanese domestic development pipeline. The private company is based in Tokyo, Japan. The company's description states that it is a page of the clinical trial guide, which suggests that it is involved in the development and testing of new pharmaceutical products. | Health Technology |
| Export-Import Bank of Japan | Finance |
